Moderna: Successful Study Data on Personalized Cancer Vaccine Triggers 100% Stock Surge!
Reading Time: 3 minutes
Successful Phase 3 study INTerpath-001 with Intismeran Autogene drives the stock up by 100%. Significant RFS and DMFS improvements in melanoma patients officially reported. The company's focus is expanding towards oncology, opening a market worth several billion USD in the medium term. Breakthrough in Oncology Moderna (MRNA) can achieve a double in stock price following the announcement of the results from the Phase 3 study INTerpath-001. Market participants are reacting to the data from the combination therapy of the personalized mRNA...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
